Target Amount vs Assigned Regimen in Retatrutide Trials
A trial’s target amount is the label used for an assigned group. The study protocol specifies how participants were monitored and how the assigned intervention was managed over time.
A trial’s target amount is the label used for an assigned group. The study protocol specifies how participants were monitored and how the assigned intervention was managed over time.
Readers may encounter GLP-3 as a catalog or search term. The clinical literature names the investigational molecule retatrutide or LY3437943 and identifies its targets as GLP-1, GIP and glucagon receptors.
Retatrutide obesity studies evaluated a once-weekly investigational intervention. Measurements used for the primary outcome were collected at prespecified follow-up points.
ClinicalTrials.gov records contain a study identifier, planned outcomes, eligibility rules and sponsor-provided status information. The registration lets readers trace a protocol across news reports and papers.
In the Phase 2 obesity trial, gastrointestinal adverse events were the most common and were dose related. The paper also described changes in heart rate during follow-up.
Phase 2 obesity research tested multiple retatrutide groups against placebo and characterized weight change and adverse events. Phase 3 studied larger populations under new protocols.
Retatrutide showed substantial weight reductions in placebo-controlled obesity trials. Tirzepatide has its own randomized obesity studies, including SURMOUNT-1, with different populations and time points.
The randomized Phase 2 trial enrolled 338 adults and compared several retatrutide groups with placebo. At week 48 the 12 mg group had an estimated mean weight change of −24.2%, compared with −2.1% with placebo.
A placebo-adjusted comparison subtracts the estimated placebo change from the estimated intervention change within a trial. The result is expressed in percentage points when the original outcome is percent change.
At 24 weeks, the Phase 2 paper reported an estimated mean change of −17.5% in the 12 mg group and −1.6% in the placebo group. This time point was specified for the primary weight endpoint.